Development of immunization policy and its implementation in the United Kingdom: How a centrally planned and implemented vaccine strategy works to ensure steady supplies of critical vaccines in the United Kingdom

Health Affairs

Volumn 24, Issue 3, 2005, Pages 744-754

  Salisbury, David M ^a  

^a United Kingdom Department of Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; VACCINE;

DISEASE CONTROL; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; IMMUNIZATION; MENINGITIS; ORGANIZATION; REVIEW; UNITED KINGDOM;

GREAT BRITAIN; HEALTH POLICY; IMMUNIZATION PROGRAMS; POLICY MAKING; STATE MEDICINE;

EID: 20044377964     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.744     Document Type: Review

References (26)

1. See the Joint Committee on Vaccination and Immunisation (JCVI) home page, www.advisorybodies.doh.gov.uk/jcvi.
2. www.advisorybodies.doh.gov.uk/jcvi Ibid.
3. D.M. Salisbury, P.C.L. Beverley, and E. Miller, "Vaccine Programmes and Policies," British Medical Bulletin 62 (2002): 201-211.
4. E. Miller, D.M. Salisbury, and M. Ramsay, "Planning, Registration, and Implementation of an Immunisation Campaign against Meningococcal Serogroup C Disease in the U.K.: A Success Story," Vaccine 20, Supp. 1 (2002): S58-S67.
5. W.J. Edmunds et al., "The Potential Cost-Effectiveness of Acellular Pertussis Booster Vaccination in England and Wales," Vaccine 20, no. 9-10 (2002): 1316-1330.
6. A. Melegaro and W.J. Edmunds, "Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccination in England and Wales," Vaccine 22, no. 31-32 (2004): 4203-4214.
7. C.L. Trotter and W.J. Edmunds, "Modelling Cost Effectiveness of Meningococcal Serogroup C Conjugate Vaccination Campaign in England and Wales," British Medical Journal 324, no. 7341 (2002): 809.
8. D.M. Salisbury and S. Dittman, "Immunization in Europe," in Vaccines, 3d ed., ed. S. Plotkin and W. Orenstein (Philadelphia: W.B. Saunders, 1999), 1033-1046.
9. D.M. Salisbury and J.-M. Olivé, "Immunization in Europe," in Vaccines, 4th ed., ed. S. Plotkin and W. Orenstein (Philadelphia: W.B. Saunders, 2004), 1387-1406.
10. National Audit Office, Modern Policy Making: Ensuring Policies Deliver Value for Money, 1 November 2001, www.nao.org.uk/publications/nao_reports/01-02/ 0102289.pdf report (28 February 2005).
11. E. Miller et al., "Effect of Schedule on Reactogenicity and Antibody Persistence of Acellular and Whole-Cell Pertussis Vaccines: Value of Laboratory Tests as Predictors of Clinical Performance," Vaccine 15, no. 1 (1997): 51-60.
12. E. Miller, "Overview of Recent Clinical Trials of Acellular Pertussis Vaccines," Biologicals 27, no. 2 (1999): 79-86.
13. M. Brisson and W.J. Edmunds, "Varicella Vaccination in England and Wales: Cost-Utility Analysis," Archives of Disease in Childhood 88, no. 10 (2003): 862-869.
14. S.L. Thomas, J.G. Wheeler, and A.J. Hall, "Contacts with Varicella or with Children and Protection against Herpes Zoster in Adults: A Case-Control Study," Lancet 360, no. 9334 (2002): 678-682.
15. JCVI Minutes, 1 October 2004, www.advisorybodies.doh.gov.uk/jcvi/ mins011004.htm (16 February 2005).
16. Department of Health, "New Meningitis C Vaccine for Schoolchildren and Young Babies," Press Release, 11 January 1999, www.dh.gov.uk/ PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID= 4025878&chk=gfK7OY (28 February 2005).
17. National Audit Office, Procurement of Vaccines by the Department of Health, 9 April 2003, www.nao.org.uk/publications/nao_reports/02-03/0203625.pdf (28 February 2005).
18. CDC, National Immunization Program, "Current Vaccine Delays and Shortages," 14 March 2005, www .cdc.gov/nip/news/shortages/default.htm (18 March 2005).
19. Chief Medical Officer Letter, "Planned Hib Vaccination Catch-Up Campaign: Further Information," 10 April 2003, www.dh.gov.uk/assetRoot/04/ 01/36/42/04013642.pdf (28 February 2005).
20. Department of Health, "New Vaccinations for the Childhood Immunisation Programme," 10 August 2004, www.dh.gov.uk/assetRoot/04/08/73/ 47/04087347.pdf (28 February 2005).
21. D.M. Salisbury, "The Consumer's Perspective," in Vaccines: Preventing Disease and Protecting Health, ed. C. de Quadros, Scientific and Technical Pub. no. 596.2004 (Washington: Pan American Health Organization, 2004), 310-317
22. J. Yarwood et al., "Tracking Mothers' Attitudes to Childhood Immunisation, 1991 to 2001," Vaccine (forthcoming).
23. D.M. Salisbury and J. Yarwood, "Public Perception of Immunisation," Lancet 363, no. 9417 (2004): 1324.
24. M.E. Ramsay et al., "Efficacy of Meningococcal Serogroup C Conjugate Vaccine in Teenagers and Toddlers in England," Lancet 357, no. 9251 (2001): 195-196.
25. C.L. Trotter, M.E. Ramsay, and E.B. Kaczmarski, "Meningococcal Serogroup C Conjugate Vaccination in England and Wales: Coverage and Initial Impact of the Campaign," Communicable Disease and Public Health 5, no. 3 (2002): 220-225.
26. E. Miller, P. Waight, and P. Farrington, "Safety Assessment Post-Licensure," in Developments in Biological Standardization, vol. 9 (Basel: Karger, 1998), 2535-2543.